Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience

• DOI: 10.1038/srep36261
• Publication Date: 2016-10-31T11:21:27Z
• Authors: Hai Wei Wu; Xuan Wang; Ling Zhang; Hai Guang Zhao; Yan An Wang; Li Xin Su; Xin Dong Fan; Jia Wei Zheng
• Keywords: Male; Infant; Interferon-alpha; Kasabach-Merritt Syndrome; Article; Disease-Free Survival; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Child, Preschool; Hemangioendothelioma; Humans; Female; Sarcoma, Kaposi; Follow-Up Studies

AbstractKaposiform hemangioendothelioma (KHE) is a relatively rare vascular tumor with an aggressive and infiltrating nature. Previous studies have revealed an exclusive relationship between KHE and Kasabach-Merritt Phenomenon (KMP), which is associated with high morbidity and mortality. No universally accepted treatment modality exists for refractory KHE with or without KMP. The aim of this study was to evaluate the safety and efficacy of interferon-alpha (IFN-α) therapy for treatment of refractory KHE. Twelve consecutive patients with KHE were treated with subcutaneous injections of IFN-α after other treatments had failed. Eleven patients exhibited a reduction in tumor size of more than 50%, and the platelet count for all five patients with KMP returned to normal level after IFN-α therapy. The duration of IFN-α treatment ranged from 3 months to 9 months (mean: 6.3 months). The response time for IFN-α treatment ranged from 10 days to 5 weeks (mean: 3.6 weeks). Additionally, no severe complications, such as neurological damage or spastic diplegia, were observed in these patients. In conclusion, our study suggested that IFN-α therapy is effective and safe for refractory KHE, and IFN-α may be used as an alternative after other treatments have failed.